Lebowitz Peter F 4

What Happened

• Peter F. Lebowitz, a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a derivative award of 63,350 shares on 2026-03-24. The award is reported at a price of $0.00 (no cash paid at grant).
• This is an equity compensation grant (reported as code "A"), not an open-market purchase or sale. There was no immediate sale or cash exercise associated with this filing.

Key Details

• Transaction date: 2026-03-24; Form 4 filed: 2026-03-26 (timely filing).
• Grant amount: 63,350 derivative shares; reported price: $0.00.
• Vesting: Per filing footnote, 1/36th of the shares vest on each monthly anniversary beginning March 24, 2026 (monthly vesting over 36 months).
• Shares owned after the transaction: not specified in the provided filing summary.
• No 10b5-1 plan, tax-withholding event, or immediate sale noted in the report.

Context

• The award is a time-based derivative grant that vests monthly over three years; typically these are restricted stock units or similar time-based equity awards. Because vesting is spread over time, the shares are not all owned outright immediately and will vest only if the director remains in service.
• This type of transaction is common for director compensation and is generally a retention/compensation event rather than a direct bullish purchase signal.